Cagrilintide / Retatrutide
Cagrilintide / Retatrutide is a combination of cagrilintide, an amylin analog, and retatrutide, a triple GLP-1, GIP and glucagon agonist, sold pre-blended in one vial or as separate vials. It is discussed for weight management, and no clinical trial has tested the two together.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
At a glance
- Cagrilintide + Retatrutide
- Metabolic support
- subcutaneous
- Not yet audited here; the reference library calls it emerging
- Sources differ. See the source
How much to draw
Full calculator →The reference does not report a single injectable amount for Cagrilintide / Retatrutide, so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Cagrilintide / Retatrutide or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Retatrutide 12 mg/week + Cagrilintide 2.4 mg/week (maintenance); pre-blend most common as 12.5 mg retatrutide + 2.5 mg cagrilintide per vial | Once weekly24-week ramp + open-ended maintenance; community: 16-24 weeks on, 4-8 weeks off | Subcutaneous | peptidedosingprotocols.comWhat it saysHide[Source: peptidedosingprotocols.com] |
- Once weekly24-week ramp + open-ended maintenance; community: 16-24 weeks on, 4-8 weeks off
- Subcutaneous
- peptidedosingprotocols.com
What it saysHide
[Source: peptidedosingprotocols.com]
- Pre-blend (15 mg vial: 12.5 mg retatrutide + 2.5 mg cagrilintide): add 2.5 mL bacteriostatic water (BAC water) slowly down the vial wall; resulting concentration is 5.0 mg/mL retatrutide + 1.0 mg/mL cagrilintide (6.0 mg/mL total blend). Both compounds use U-100 insulin syringes. BAC water is added slowly down the vial wall. Separate vials each use 1-2 mL BAC water per vial. Reconstituted vials are stable for 28-30 days at 2-8 °C.
We have not published an audit on Cagrilintide / Retatrutide. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Retatrutide lowers appetite, slows the stomach and raises energy use, while cagrilintide adds a separate fullness signal in the hindbrain. Researchers link this to four receptor pathways: GLP-1, GIP and glucagon for retatrutide, and amylin for cagrilintide. The logic is borrowed from the CagriSema program, where adding cagrilintide to semaglutide raised average weight loss from 14.9% to 20.4%. No clinical trial has tested cagrilintide and retatrutide together, so the evidence for the pair is theoretical.
Combines amylin-receptor agonism with triple incretin agonism; studied for appetite regulation and weight management.
Reported side effects
Seen in studies: dysesthesia, meaning tingling, numbness or prickling, has been linked to retatrutide dose increases in clinical trials. No trial has tested the two compounds together.
Reported by users: nausea, vomiting, constipation and trouble stepping doses up, described as the biggest practical concern with the stack. Both compounds slow stomach emptying, and gut effects often peak when both are being raised, around weeks 13-16 of the staggered schedule.
Not ruled out: the net effect on blood sugar, because the interaction between retatrutide's glucagon receptor activity and cagrilintide's calcitonin-related signaling has not been studied. The source lists severe abdominal pain, persistent vomiting, fainting, dehydration, chest pain and allergic symptoms as needing immediate medical review.
Who should avoid it
People with diabetes: diabetes medicines may need clinician review if glucose changes with reduced food intake.
People with kidney disease: listed as a caution in the reference library, with no reason given.
People with a history of gallbladder problems or pancreatitis: listed as a caution in the reference library, with no reason given.
People with liver disease: listed as a caution in the reference library, with no reason given.
People with cardiovascular concerns: listed as a caution in the reference library, with no reason given.
People already using semaglutide or tirzepatide: retatrutide already covers GLP-1, so another GLP-1 compound adds redundancy and side-effect burden without extra benefit.
What gets monitored
A1c (baseline); Fasting glucose (follow-up); Comprehensive metabolic panel / CMP, kidney function, liver enzymes, electrolytes, glucose (baseline); Lipid panel (follow-up); Blood pressure and resting heart rate (follow-up). Repeat metabolic markers after 4-12 weeks, with closer review during dose escalation or major appetite changes. For longer protocols, review metabolic, kidney, liver, and cardiovascular trends every 3-6 months with a clinician. (reported by peptidedosingprotocols.com)
Common questions
What is the cagrilintide + retatrutide stack?
It is a two-compound research protocol pairing cagrilintide, an amylin analog that signals fullness through the hindbrain, with retatrutide, a triple GLP-1, GIP and glucagon agonist. Together they cover four receptor pathways. No clinical trial has tested this exact pair, though the related CagriSema Phase 3 trial showed that adding amylin to a GLP-1 drug improved weight loss.
What is 'cag peptide' or 'reta/cag'?
Cag is short for cagrilintide, and reta/cag is shorthand for this two-compound stack. Supplier names such as ma-3rt/cag, fg3-r/cag, GLP-3/cag, 3R + cagri and AO-3RT/cag all refer to a retatrutide and cagrilintide pre-blend. The source says the mg breakdown on the vial label is what identifies the product, not the brand name.
How much cagrilintide do you take with retatrutide?
Reported amounts and schedules for Cagrilintide / Retatrutide differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
What is in a 12.5 mg / 2.5 mg reta/cag blend vial?
A standard 5:1 pre-blend is described as 12.5 mg retatrutide plus 2.5 mg cagrilintide, 15 mg total in one vial. Mixed with 2.5 mL of bacteriostatic water, that gives 5.0 mg/mL retatrutide and 1.0 mg/mL cagrilintide. A 0.40 mL draw then holds 2.0 mg retatrutide and 0.4 mg cagrilintide.
How do you reconstitute the 12.5 mg / 2.5 mg reta-cag blend?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
Should I use a pre-blended vial or separate vials?
The source describes a pre-blend as simpler: one injection, one reconstitution and one calculation. Its trade-off is the fixed 5:1 ratio, so one compound cannot be raised without raising the other. The source describes separate vials as the safer option for most first-time stack users, since they allow staggered dosing with cagrilintide added at Week 9.
Can you take cagrilintide and retatrutide together?
The source says both are dosed once weekly, and that same-day injection at different sites is standard in community protocols. Both slow digestion, so gut side effects can add up. Community protocols describe retatrutide alone for the first 8 weeks, then cagrilintide added at 0.25 mg with slow increases, and no clinical trial has tested the pair.
What is the starting dose for cagrilintide when stacking with retatrutide?
Reported amounts and schedules for Cagrilintide / Retatrutide differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
Sources
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
Cagrilintide / Tirzepatide is a combination of cagrilintide, an amylin analog, and tirzepatide, a dual GIP and GLP-1 agonist, each given once weekly from its own vial. It is discussed for weight management, with one study in obese rats and no human trial of the two together.
CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, given once weekly. It has been studied for weight management in people in Phase 3 trials and is not FDA-approved as of June 2026.
Mazdutide, also called IBI362, is an investigational lab-made peptide drug that switches on two metabolic hormone receptors at once. It is being studied in clinical trials as a once-weekly injection for weight management and metabolic health.
Retatrutide is an investigational once-weekly injectable that acts on three hormone receptors at once: GLP-1, GIP and glucagon. It is being studied for weight and metabolic outcomes in adults with obesity, type 2 diabetes and fatty liver disease.
Semaglutide is a lab-made copy of GLP-1, a gut hormone that helps the body manage hunger and blood sugar. It is among the most heavily studied weight-loss and diabetes medicines, with trial programmes covering more than 45,000 participants.
Tirzepatide is a lab-made peptide that switches on two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is studied in people for weight management and blood sugar control, including in the SURPASS and SURMOUNT trial programs.